<DOC>
	<DOCNO>NCT01948297</DOCNO>
	<brief_summary>This study primarily design assess safety tolerability Debio1347 ( CH5183284 ) patient advance solid malignancy , whose tumour alteration Fibroblast Growth Factor Receptor ( FGFR ) 1 , 2 3 gene , standard treatment exist indicate . The main objective Part A identify dose-limiting toxicity ( DLTs ) estimate maximum tolerate dose ( MTD ) base safety tolerability Debio1347 orally administer daily patient , order determine recommend dose . The main objective Part B evaluate safety profile recommend dose , large cohort patient .</brief_summary>
	<brief_title>Debio 1347-101 Phase I Trial Advanced Solid Tumours With Fibroblast Growth Factor Receptor ( FGFR ) Alterations</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Meets protocolspecified criterion qualification contraception Is willing able remain confine study unit entire duration treatment period comply restriction relate food , drink medication Voluntarily consent participate provide write informed consent prior protocolspecific procedure Has history current use overthecounter medication , dietary supplement , drug ( include nicotine alcohol ) outside protocolspecified parameter Has sign , symptom history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff 2. safety wellbeing participant 's offspring ( pregnancy breastfeed ) 3. analysis result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>